J&J Will Not Enforce AIDS Drug Patents in Poor Countries

by Kathy Jones on  November 30, 2012 at 3:27 PM AIDS/HIV News
RSS Email Print This Page Comment bookmark
Font : A-A+

In a welcome announcement, Johnson & Johnson has said it would not enforce its patents on its AIDS drug Prezista in the world's poorest countries and throughout sub-Saharan Africa.
 J&J Will Not Enforce AIDS Drug Patents in Poor Countries
J&J Will Not Enforce AIDS Drug Patents in Poor Countries

Offering cost relief to people infected with the HIV virus, J&J said it wanted to assure manufacturers that they can freely produce the generic version of the drug, darunavir, for sale in poor countries without fear of being accused of patent violation.

The new policy applies only to countries defined by the United Nations as Least Developed Countries, and also to sub-Saharan Africa, where the AIDS epidemic has been most intense.

"This new policy anticipates a greater future need to supply affordable generic versions of darunavir for the treatment of people living with HIV in the territory," J&J said, two days ahead of the annual World AIDS Day.

"We believe... that intellectual property should not be a barrier to ensuring a sustainable supply of medically acceptable darunavir in the world's poorest countries," Paul Stoffels, J&J's worldwide chairman for pharmaceuticals, said in a statement.

J&J markets the antiretroviral drug as Prezista through its subsidiary Janssen Pharmaceuticals.

It is often administered together with other antiretroviral drugs, like the already widely available ritonavir, to protect HIV-infected patients from developing full-blown AIDS.

At the official US wholesale price, Prezista costs a user more than $34 a day or some $12,400 a year.

As a generic, though, the price can drop by 90 percent or more, Stoffels told AFP. Darunavir is currently produced by South Africa's Aspen Pharmaceuticals and sold locally for about $2.22 a dose, he said.

Stoffels said he expected the demand for darunavir to soar, with production launched in 10-15 factories worldwide to supply poor countries covered under the new patent protection announcement.

Source: AFP

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Oral Health And AIDS Drug Toxicity AIDS/HIV AIDS/HIV - Epidemiology AIDS/HIV - Clinical Features AIDS/HIV - Health Education AIDS/HIV - Prevention And Transmission AIDS / HIV - Treatment AIDS/HIV- Lab Tests and Faqs AIDS - Initial Theories and Disease Progression 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive

Loading...